SCHEMBL142464

SCHEMBL142464

COc1ccc(-c2cc(C#N)c3[nH]c4cc(OC)ccc4c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.50
MAOB P27338 1/20 0.50
DYRK1A Q13627 13/20 0.49
CLK1 P49759 4/20 0.49
CLK2 P49760 4/20 0.49
CLK3 P49761 4/20 0.49
CDK5 Q00535 4/20 0.49
CDK5R1 Q15078 4/20 0.49
CLK4 Q9HAZ1 4/20 0.49
DYRK1B Q9Y463 4/20 0.49
ACHE P22303 2/20 0.48
KDM4E B2RXH2 1/20 0.48
DYRK3 O43781 1/20 0.48
CCNT1 O60563 1/20 0.48
CCNB2 O95067 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CDK1 P06493 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADRA2A P08913 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142234 0.74 JAK2 (0.68) DYRK1ACLK1CDK5CDK5R1JAK2
SCHEMBL23371495 0.72 DYRK1A (0.54) MAOADYRK1ACLK1CLK2CLK3
SCHEMBL16450984 0.71 STING1 (0.67) MAOADYRK1ACLK1CLK2CLK3
SCHEMBL2330779 0.71 KDM4E (0.68) MAOADYRK1ACLK1CLK2CLK3
SCHEMBL29533596 0.71 KDM4E (0.68) MAOADYRK1ACLK1CLK2CLK3
SCHEMBL7095254 0.69 PGR (0.55) MAOAMAOBKDM4EALDH1A1HPGD
SCHEMBL29662946 0.69 PGR (0.55) MAOAMAOBKDM4EALDH1A1HPGD
SCHEMBL982356 0.68 KDM4E (0.53) MAOAMAOBDYRK1ACLK1CLK2
SCHEMBL578915 0.68 IMPDH2 (0.59) DYRK1ACLK1CLK2CLK3CDK5
SCHEMBL28756446 0.68 PGR (0.48) MAOAMAOBKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 MAOA 2218/4885MAOB 1546/4885DYRK1A 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.